TABLE 1.

Cumulative Absorbed Doses (Gy/MBq) of ¹⁷⁷Lu-L804-IAB2MA and ¹⁷⁷Lu-DOTA-IAB2MA at 72 Hours After Injection and Tumor-to-Organ Ratios

Organ	¹⁷⁷Lu-L804-IAB2MA	¹⁷⁷Lu-DOTA-IAB2MA	P
Imalytics Preclinical^*
Tumor	0.21 ± 0.02	0.33 ± 0.01	0.0049
Kidney	0.20 ± 0.01	0.43 ± 0.04	0.0039
Liver	0.22 ± 0.01	0.32 ± 0.04	0.0469
Lung	0.02 ± 0.008	0.05 ± 0.02	0.4706
Muscle	0.03 ± 0.007	0.07 ± 0.005	0.0118
Tumor-to-kidney	1.05 ± 0.03	0.77 ± 0.10	0.0638
Tumor-to-liver	0.96 ± 0.07	1.05 ± 0.15	0.6471
Tumor-to-lung	13.71 ± 7.54	14.9 ± 9.24	0.9756
Tumor-to-muscle	6.74 ± 0.89	4.68 ± 0.26	0.0805
MIRDCalc^†
Tumor	0.31 ± 0.03	0.73 ± 0.07	0.0008
Kidney	0.22 ± 0.006	0.94 ± 0.04	<0.0001
Liver	0.51 ± 0.01	0.76 ± 0.03	0.0003
Heart	0.13 ± 0.005	0.21 ± 0.01	0.0005
Spleen	0.14 ± 0.004	0.64 ± 0.05	0.0009
Salivary glands	0.09 ± 0.005	0.23 ± 0.008	<0.0001
Tumor-to-kidney	1.39 ± 0.11	0.78 ± 0.07	0.0027
Tumor-to-liver	0.60 ± 0.06	0.96 ± 0.08	0.0130
Tumor-to-heart	2.30 ± 0.19	3.46 ± 0.26	0.0122
Tumor-to-spleen	2.24 ± 0.20	1.16 ± 0.11	0.0024
Tumor–to–salivary glands	3.64 ± 0.50	3.11 ± 0.31	0.3977